The combined therapy with Olmesartan and Azelnidipin in the hypertensive patients with sleep apnea syndrome (SAS)

The combined therapy with Olmesartan and Azelnidipin in the hypertensive patients with sleep apnea syndrome (SAS) - The combined therapy with Olmesartan and Azelnidipin in the hypertensive patients with sleep apnea syndrome (SAS)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007171

Enrollment

100

Registered

2012-02-01

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Apnea Syndrome

Interventions

Add Azelnidipine (8-16mg/day) to patients treated with olmesartan(20mg/day) Add Amlodipine(2.5-5mg/day) to patients treated with olmesartan(20mg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The hypertensive patients with SAS. 2) Hypertensive patients who did not reach target BP(defined by JSH2009) in spite of monotherapy of Olmesaltan. 3) Patients wiht AHI of15-20 or patients for whom CPAP introduction is improper at 40 or more AHI

Exclusion criteria

Exclusion criteria: 1) The patient who is taking azelnidipine or amlodipine 2) The patient who has critical liver disease. (AST or ALT is 100 or more IU/L) 3) The patient who has a critical renal disease (the patient under dialysis enforcement is included). (more than BUN 25mg/dL or more than serum creatinine 2.0mg/dL) 4) Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
Blood pressure(Clinic BP,Home BP)	—

Secondary

Measure	Time frame
PSG, AHI, noradrenalin, cortisol, Plasma aldosterone concentration, Plasma renin activity, ACTH, BNP,blood sugar level, renal function(the very-small-quantity albumin in urine, albuminuria, eGFR), Salt intake,HOMA-R, PAI-1, adiponectin	—

Countries

Japan

Contacts

Public ContactYoshiyu Takeda

Kanazawa University Hospital Department of Endocrinology and Metabolism

076-265-2252

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026